LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

Rhea-AI Summary

LENZ (NASDAQ: LENZ) launched the consumer campaign “Make it VIZZable” on Jan 14, 2026, naming Sarah Jessica Parker as brand ambassador for VIZZ (aceclidine ophthalmic solution) 1.44%. The campaign highlights SJP’s personal experience with age-related blurry near vision and demonstrates VIZZ as a prescription, once-daily alternative to reading glasses.

Clinical highlight: in the CLARITY Phase 3 trial, 93% of participants achieved 20/40 or better near vision within 30 minutes, lasting up to 10 hours. VIZZ is available nationwide by prescription; free samples are offered through participating eye doctors and www.VIZZ.com.

Positive

• Phase 3 readout: 93% achieved 20/40 near vision
• Onset: improvement within 30 minutes
• Availability: nationwide by prescription with free samples

Negative

• Prescription-only: requires eye doctor visit to obtain
• Effect duration: improvement lasts up to 10 hours (not permanent)

News Market Reaction

+11.99%

37 alerts

+11.99% News Effect

+6.4% Peak in 4 hr 32 min

+$63M Valuation Impact

$584M Market Cap

1.3x Rel. Volume

On the day this news was published, LENZ gained 11.99%, reflecting a significant positive market reaction. Argus tracked a peak move of +6.4% during that session. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $63M to the company's valuation, bringing the market cap to $584M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Near-vision duration: up to 10 hours Onset time: 30 minutes Near-vision response rate: 93% +5 more

8 metrics

Near-vision duration up to 10 hours Effect duration of VIZZ near-vision improvement

Onset time 30 minutes Time for participants to achieve improved near vision in CLARITY Phase 3

Near-vision response rate 93% CLARITY Phase 3 participants achieving 20/40 or better near vision

Near-vision threshold 20/40 Near-vision acuity level achieved by CLARITY Phase 3 participants

Pupil size target sub-2mm pupil Pupil size achieved to extend depth of focus with VIZZ

Drug concentration 1.44% Aceclidine ophthalmic solution strength in VIZZ

Affected population 128 million Americans People with age-related blurry near vision mentioned in campaign

Age group 45 years and older Age group described as affected by age-related blurry near vision

Market Reality Check

Price: $14.22 Vol: Volume 747,438 is 27% bel...

normal vol

$14.22 Last Close

Volume Volume 747,438 is 27% below the 20-day average of 1,023,264 (relative volume 0.73). normal

Technical Shares at $16.60 are trading below the 200-day MA of $30.42 and 67.06% below the 52-week high.

Peers on Argus

LENZ is up 6.62% while peers show mixed moves: DNTH +14.7%, ELVN +3%, AMLX +1.78...

LENZ is up 6.62% while peers show mixed moves: DNTH +14.7%, ELVN +3%, AMLX +1.78%, TRML flat, TRVI slightly negative. This points to a stock-specific reaction rather than a broad biotechnology move.

Historical Context

5 past events · Latest: Jan 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 07	Earnings update	Positive	-3.2%	Preliminary Q4 2025 results and early VIZZ launch metrics.
Jan 05	Commercial partnership	Positive	+3.0%	Exclusive Middle East commercialization agreement for VIZZ.
Dec 01	Regulatory filing	Positive	-0.4%	South Korea NDA submission for VIZZ using Phase 3 data.
Nov 25	Investor conferences	Neutral	+2.8%	Presentations at multiple early-December healthcare conferences.
Nov 05	Earnings & approval	Positive	-23.5%	Q3 2025 results with FDA approval and early VIZZ launch details.

Pattern Detected

Positive fundamental and clinical updates have sometimes seen negative reactions (notably earnings), while partnership and conference news tended to align modestly positive with price.

Recent Company History

Over the last few months LENZ has focused on commercializing VIZZ and expanding its reach. An earnings update on Nov 05 2025 highlighted FDA approval and early launch metrics but coincided with a -23.46% move. Subsequent conference participation on Nov 25 2025 saw a +2.81% reaction. International expansion and regulatory progress continued with an NDA submission for South Korea on Dec 01 2025 and a Middle East partnership on Jan 05 2026. Preliminary Q4 2025 results on Jan 07 2026 again drew a -3.2% move despite commercial milestones. Today’s consumer campaign fits into this ongoing commercialization story.

Market Pulse Summary

The stock surged +12.0% in the session following this news. A strong positive reaction aligns with a...

Analysis

The stock surged +12.0% in the session following this news. A strong positive reaction aligns with a high-profile consumer launch featuring a well-known brand ambassador and clear Phase 3 data, including a 93% near-vision response and effects lasting up to 10 hours. Historically, LENZ sometimes faced selloffs on positive earnings and approval news, so a sustained move would depend on how this campaign converts into prescriptions. With short interest around 15.82% and shares still 67.06% below the 52-week high, positioning risk and volatility remained important considerations.

Key Terms

aceclidine, ophthalmic solution, pupil-selective miotic, iris sphincter muscle, +2 more

6 terms

aceclidine medical

"VIZZ™ (aceclidine ophthalmic solution) 1.44%. As part of the campaign..."

Aceclidine is a medication that activates certain receptors in the eye to tighten the pupil and help open fluid drainage channels, which lowers pressure inside the eye and is used to treat glaucoma. Think of it as a tiny valve adjustment that helps fluid flow out more easily. For investors, developments around aceclidine—such as clinical trial results, regulatory approvals, or licensing—can affect the value and prospects of companies working on eye-care treatments.

ophthalmic solution medical

"VIZZ™ (aceclidine ophthalmic solution) 1.44%. As part of the campaign..."

An ophthalmic solution is a liquid medicine formulated to be placed in the eye, like eye drops, used to treat conditions such as infections, inflammation, pressure changes, or dry eye. Investors track these products because their approval, safety record, manufacturing quality and patent status determine sales potential and competition—think of it like a packaged household remedy whose shelf life, rules and maker reputation affect its market value.

pupil-selective miotic medical

"aceclidine, differentiated by its mechanism of action as a predominantly pupil-selective miotic..."

A pupil-selective miotic is an eye medication that narrows the pupil by acting mainly on the muscles controlling pupil size, without significantly affecting other eye functions. For investors, it matters because such targeted drugs can offer effective symptom relief (for conditions like light sensitivity or to improve near vision) with fewer side effects, which can speed regulatory approval, broader clinical use, and commercial uptake—akin to a tool that fixes one problem without disturbing nearby parts.

iris sphincter muscle medical

"VIZZ contracts the iris sphincter muscle, resulting in a pinhole effect..."

A circular muscle located at the edge of the colored part of the eye (the iris) that tightens to make the pupil smaller, controlling how much light enters the eye. It matters to investors because damage, disease, or drugs that affect this muscle can change vision and drive demand for treatments, devices, or approvals—so developments involving the iris sphincter muscle can influence the commercial prospects and regulatory risk of ophthalmology products.

myopic shift medical

"extends depth of focus to significantly improve near vision without causing a myopic shift."

A myopic shift is a change in a person’s eyesight that makes distant objects look blurrier, like a camera lens suddenly focusing closer. For investors, it matters when reported in clinical trials, product labels, or safety updates because it can signal a medication or device side effect that affects patient outcomes, regulatory approval, market demand, and potential liability, similar to an unexpected defect altering a product’s usability and sales prospects.

Phase 3 clinical trial medical

"In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40..."

A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.

AI-generated analysis. Not financial advice.

Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours

The “Make it VIZZable” campaign features SJP enjoying the everyday convenience of clear near vision provided by using the VIZZ eye drops.

VIZZ is available nationwide by prescription through eye doctors; visit VIZZ.com to learn more and to find a local provider offering a free sample

SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), today announced the launch of “Make it VIZZable”, the VIZZ consumer campaign with award-winning actor, producer and publisher, Sarah Jessica Parker (“SJP”) as a brand ambassador for VIZZ™ (aceclidine ophthalmic solution) 1.44%. As part of the campaign, SJP will detail her own experiences with age-related blurry near vision and the ways in which VIZZ has made a real difference in her life.

“My age-related blurry near vision was a daily frustration, it got in the way of everything,” said Parker. “It’s so nice not having to reach for my reading glasses all the time; life just becomes more efficient. Life’s everyday moments like checking my phone, doing my makeup, or my passion to read - everything feels easier. This is a gamechanger. My eye doctor was really excited about VIZZ, and I can see why. It’s a real solution for people who want more ease, freedom and confidence in their day-to-day life.”

SJP is one of the 128 million Americans who know all too well how age-related blurry near vision can get in the way of work, daily tasks and everyday moments. It was around 15 years ago when she noticed her nightly reading was becoming a strain. She was frustrated that she was no longer able to read comfortably without reading glasses, but she accepted them as her new way of life and an inevitable part of aging, until she started using VIZZ.

“Sarah Jessica’s experience with age-related blurry near vision is so universal and relatable, we knew she would be a perfect partner in this campaign,” said Eef Schimmelpennink, CEO of LENZ Therapeutics. “We are honored to partner with SJP to introduce a unique new alternative to reading glasses for the millions affected by blurry near vision as they age. With VIZZ, we’re excited to provide a revolutionary option that helps people regain the visual freedom they’ve been missing.”

As brand ambassador, Parker’s story, told with her iconic wit and charm, will be the driving force behind the company’s ‘Make it VIZZable’ campaign, which highlights how much more convenient life can be when age-related blurry near vision isn’t getting in the way of everyday moments. The campaign features Parker in the streets of New York City, demonstrating the eye drops in action as she reads her text messages, scans price tags and reviews scripts without reading glasses. More details can be found about her story on www.VIZZ.com and on Facebook, Instagram, TikTok, YouTube and LinkedIn.

Age-related blurry near vision can pose significant challenges in daily life for those 45 years and older. Although the progression of age-related blurry near vision is gradual, those living with it often experience an abrupt change in their daily life as the symptoms become more pronounced, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work.

VIZZ is powered by aceclidine, differentiated by its mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle, resulting in a pinhole effect and uniquely achieves a sub-2mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift. In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes and lasted up to 10 hours. This level of near vision can restore the ability to read a phone screen and other everyday fine print without the assistance of reading glasses.

For more information about the partnership, VIZZ and the full prescribing information, please visit www.VIZZ.com.

About Presbyopia
Presbyopia is the inevitable loss of near vision associated with aging. It impacts the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity of the lens reduces the ability of the lens to focus incoming light from near objects onto the retina. Adults over age 50 lose, on average, 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses.

About VIZZ (aceclidine ophthalmic solution) 1.44%
VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. Aceclidine is the sole active ingredient in VIZZ and provides rapid and durable near vision improvement. VIZZ is preservative-free and provided in single-dose vials. VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision.

VIZZ Indication and Important Safety Information

INDICATION
VIZZ (aceclidine ophthalmic solution) 1.44% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults.

IMPORTANT SAFETY INFORMATION

• Do not use VIZZ if allergic to any of the ingredients.
• To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use.
• Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes.
• If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart.
• Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear.
• Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced.
  
  

ADVERSE REACTIONS

The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.

For additional information, please see the full Prescribing Information available at www.VIZZ.com.

About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com. 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “poised,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. Forward-looking statements in this press release include statements regarding the timing and availability of VIZZ, including the VIZZ DTC campaign; potential market size for VIZZ; its ability to meet patient needs and become standard of care; LENZ commercialization plans, including international partnering plans, and the quotations of LENZ management. These statements are based on numerous assumptions concerning VIZZ, target markets and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements, including those risk factors described in the section titled “Risk Factors” in our Quarterly Report on Form 10-Q filed for the quarter ended September 30, 2025 and our subsequent filings with the SEC. We cannot assure you that the forward-looking statements in this press release or the assumptions upon which they are based will prove to be accurate. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, LENZ disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. 

Contact:

Media Contact:
Claire Campbell
Claire.Campbell@ruderfinn.com

Investor Contact:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cdf3e740-3bef-49bc-8145-715979517ab1

FAQ

What did LENZ announce about VIZZ on January 14, 2026?

LENZ announced the “Make it VIZZable” consumer campaign with Sarah Jessica Parker as brand ambassador for VIZZ.

What are the CLARITY Phase 3 results for LENZ’s VIZZ (LENZ)?

In CLARITY Phase 3, 93% of participants achieved 20/40 or better near vision within 30 minutes, lasting up to 10 hours.

How can patients get VIZZ (aceclidine 1.44%) from LENZ (LENZ)?

VIZZ is available nationwide by prescription from eye doctors; patients can visit VIZZ.com to find providers and request a free sample.

What does VIZZ (LENZ) do compared with reading glasses?

VIZZ is a once-daily eye drop that creates a pinhole effect to extend depth of focus, improving near vision without causing a myopic shift.

Will LENZ’s Sarah Jessica Parker campaign affect VIZZ access in 2026?

The campaign aims to raise awareness and encourage prescription uptake by showcasing real-world use and directing patients to eye doctors and VIZZ.com.